N-[6-(aminomethyl)-1-isoquinolinyl]benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: N-[6-(aminomethyl)-1-isoquinolinyl]benzamide
• 英文别名: N-[6-(aminomethyl)isoquinolin-1-yl]benzamide
• 化学式: C₁₇H₁₅N₃O
• 分子量: 277.326
• InChiKey: QKNGLZCELQISTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-[6-(aminomethyl)-1-isoquinolinyl]benzamide 在 盐酸 、 水 、 溶剂黄146 作用下， 反应 24.0h， 生成 6-(aminomethyl)isoquinolin-1-amine
  参考文献：
  名称：

  Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

  摘要：

  Fragment-based NMR screening of a small literature focused library led to identification of a historical thrombin/FactorXa building block, 17A, that was found to be a ROCK-I inhibitor. In the absence of an X-ray structure, fragment growth afforded 6-substituted isoquinolin-1-amine derivatives which were profiled in the primary ROCK-I IMAP assay. Compounds 23A and 23E were selected as fragment optimized hits for further profiling. Compound 23A has similar ROCK-1 affinity, potency and cell based efficacy to the first generation ROCK inhibitors, however, it has a superior PK profile in C57 mouse. Compound 23E demonstrates the feasibility of improving ROCK-1 affinity, potency and cell based efficacy for the series, however, it has a poor PK profile relative to 23A. (C) 2010 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.11.060
• 作为产物：
  描述：

  N-(6-formyl-1-isoquinolinyl)benzamide 在 氨 作用下， 以 四氢呋喃 为溶剂， 生成 N-[6-(aminomethyl)-1-isoquinolinyl]benzamide
  参考文献：
  名称：

  Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

  摘要：

  Fragment-based NMR screening of a small literature focused library led to identification of a historical thrombin/FactorXa building block, 17A, that was found to be a ROCK-I inhibitor. In the absence of an X-ray structure, fragment growth afforded 6-substituted isoquinolin-1-amine derivatives which were profiled in the primary ROCK-I IMAP assay. Compounds 23A and 23E were selected as fragment optimized hits for further profiling. Compound 23A has similar ROCK-1 affinity, potency and cell based efficacy to the first generation ROCK inhibitors, however, it has a superior PK profile in C57 mouse. Compound 23E demonstrates the feasibility of improving ROCK-1 affinity, potency and cell based efficacy for the series, however, it has a poor PK profile relative to 23A. (C) 2010 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.11.060

文献信息

• Heterocyclic derivatives and their use as antithrombotic agents
  申请人：Akzo Nobel N.V.

  公开号：US06194409B1

  公开（公告）日：2001-02-27

  The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is O or S; X′ being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents.

  本发明涉及抗血栓化合物，包括Q基团，其中Q具有化学式(I)，其中亚结构(i)是从(a、b和c)中选定的结构，其中X为O或S；X′独立地为CH或N；m为0、1、2或3；其中基团Q通过氧原子或可选择取代的氮或碳原子结合，或其药学上可接受的盐或前药。本发明的化合物具有治疗活性，特别是抗血栓作用剂。
• [EN] HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS<br/>[FR] DERIVES HETEROCYCLIQUES ET LEUR UTILISATION EN TANT QU'AGENTS ANTITHROMBOTIQUES
  申请人：AKZO NOBEL N.V.

  公开号：WO1998047876A1

  公开（公告）日：1998-10-29

  (EN) The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is O or S; X' being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents.(FR) La présente invention concerne des composé antithrombotiques comprenant le groupe Q correspondant à la formule (I) dans laquelle la sous-structure (i) est une structure choisie parmi (a), (b) ou (c) où X représente O ou S, X' représente indépendamment CH ou N, et m vaut 0, 1, 2 ou 3, le groupe Q étant fixé au moyen d'un atome d'oxygène ou d'un atome de carbone ou d'azote éventuellement substitué. L'invention concerne également un sel ou un promédicament de ces composés, acceptable sur le plan pharmacologique. Les compositions de l'invention sont actives sur le plan thérapeutique et constituent notamment des agents antithrombotiques.

  该发明涉及抗血栓化合物，包括具有公式（I）的Q基团，其中亚结构（i）是从（a）、（b）和（c）中选择的结构，其中X为O或S；X'独立地为CH或N；m为0、1、2或3；其中Q基团通过氧原子或可选择的取代氮或碳原子结合，或其药学可接受的盐或前药。该发明的化合物具有治疗活性，特别是抗血栓剂。
• HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS
  申请人：Akzo Nobel N.V.

  公开号：EP0975600A1

  公开（公告）日：2000-02-02
• US6194409B1
  申请人：——

  公开号：US6194409B1

  公开（公告）日：2001-02-27
• US6432955B1
  申请人：——

  公开号：US6432955B1

  公开（公告）日：2002-08-13